We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Casma Therapeutics Stock

Invest in or calculate the value of your shares in Casma Therapeutics or other pre-IPO companies through EquityZen's platform.

Get Started

Casma Therapeutics Stock (CATH)

Casma Therapeutics is a biotechnology company harnessing the natural cellular process of autophagy to design new medicines.

About Casma Therapeutics Stock

Founded

2017

Headquarters

Cambridge, MA, US

Industries

Software, Artificial Intelligence, Data and Analytics

Casma Therapeutics is a developer of a natural cellular process of autophagy to open new target areas for drug discovery and development. The company focuses on autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens as well as tries to arrest or reverse the progression of lysosomal storage disorders, muscle disorders, inflammatory disorders and neurodegeneration, enabling physicians to address unmet medical needs.

Casma Therapeutics Management

Leadership team at Casma Therapeutics

Board Member

Hiromichi Kimura

Board Of Director

Frank T. Gentile

Locked Features

Join now and verify your accreditation status to gain access to:

  • Casma Therapeutics current valuation
  • Casma Therapeutics stock price
  • Available deals in Casma Therapeutics and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Casma Therapeutics stock?

Accredited investors can buy pre-IPO stock in companies like Casma Therapeutics through EquityZen funds. These investments are made available by existing Casma Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Casma Therapeutics stock?

Shareholders can sell their Casma Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."